Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Harada

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
The Prostate|September 25, 2004
New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patientsAkihisa Yao, Mamoru Harada, Satoko Matsueda, et al.
International Immunopharmacology|March 31, 2015
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype allelesTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 11, 2007
[Acquired tumor "robustness" in the case of prostate cancer]Shigenori Homma, Masanori Noguchi, Yuji Sato, et al.
Immunobiology|October 4, 2011
Interleukin-17A is involved in enhancement of tumor progression in murine intestineKiyotetsu Oshiro, Hideyasu Kohama, Masayuki Umemura, et al.
Medical Molecular Morphology|November 22, 2023
Overexpression of SerpinB9 in non-seminomatous germ cell tumorsToshiki Anami, Yuki Ibe, Lianbo Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancersNaotake Tsuda, Kazuo Mochizuki, Mamoru Harada, et al.
International Journal of Oncology|July 26, 2006
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patientsShigenori Homma, Mamoru Harada, Hirohisa Yano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumorMasatoshi Eto, Yoriyuki Kamiryo, Ario Takeuchi, et al.
International Journal of Oncology|May 5, 2005
Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancyHiroko Takedatsu, Kohji Yoshimoto, Takashi Okamura, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the peripheryShoko Tanaka, Mamoru Harada, Takashi Mine, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
The Prostate|September 25, 2004
New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patientsAkihisa Yao, Mamoru Harada, Satoko Matsueda, et al.
International Immunopharmacology|March 31, 2015
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype allelesTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 11, 2007
[Acquired tumor "robustness" in the case of prostate cancer]Shigenori Homma, Masanori Noguchi, Yuji Sato, et al.
Immunobiology|October 4, 2011
Interleukin-17A is involved in enhancement of tumor progression in murine intestineKiyotetsu Oshiro, Hideyasu Kohama, Masayuki Umemura, et al.
Medical Molecular Morphology|November 22, 2023
Overexpression of SerpinB9 in non-seminomatous germ cell tumorsToshiki Anami, Yuki Ibe, Lianbo Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancersNaotake Tsuda, Kazuo Mochizuki, Mamoru Harada, et al.
International Journal of Oncology|July 26, 2006
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patientsShigenori Homma, Mamoru Harada, Hirohisa Yano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumorMasatoshi Eto, Yoriyuki Kamiryo, Ario Takeuchi, et al.
International Journal of Oncology|May 5, 2005
Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancyHiroko Takedatsu, Kohji Yoshimoto, Takashi Okamura, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the peripheryShoko Tanaka, Mamoru Harada, Takashi Mine, et al.
Pageof 11